Antibody News and Research

RSS

An antibody is a blood protein that is produced in response to and counteracts an antigen. Antibodies are produced in response to disease and help the body fight against the particular disease. In this way, antibodies help the body develop an immunity to disease.

Engineered immunogens show promise in inducing HIV broadly neutralizing antibodies

Using a combination of cutting-edge immunologic technologies, researchers have successfully stimulated animals' immune systems to induce rare precursor B cells of a class of HIV broadly neutralizing antibodies (bNAbs).

30 May 2024

New antibody shows promise as universal weapon against COVID-19 variants

SARS-CoV-2, the virus that causes COVID-19 disease, continues to evolve and evade current vaccine and therapeutic interventions.

29 May 2024

New type of immunotherapy shows promising preclinical results against osteosarcoma

A new type of immunotherapy, developed by UCL researchers, has shown promising preclinical results against a bone cancer called osteosarcoma, as part of a study in mice.

29 May 2024

RNA-based therapy shows promise in reducing cholesterol and triglycerides

A small interfering RNA (siRNA) investigational therapy that inhibits a gene involved in lipoprotein metabolism has been shown in a clinical trial led by Mount Sinai researchers to significantly reduce levels of different types of cholesterol and triglycerides in individuals with mixed hyperlipidemia, a condition in which fats build up in the blood.

29 May 2024

Vaccination remains crucial for preventing avian influenza spread, says study

Vaccination remains the most effective strategy for avian influenza prevention and control in humans, despite varying vaccine efficacy across strains.

29 May 2024

Novel method creates antibody-peptide inhibitor conjugates with enhanced therapeutic efficacy

Tumor cells often hijack normal physiological processes to support their growth, exploiting proteins that are in charge of essential cell functions.

29 May 2024

Targeting CD47 to improve osimertinib efficacy in EGFR mutant NSCLC

NSCLC is the leading cause of cancer deaths globally, with EGFR mutations being a common feature in these cancers.

28 May 2024

New point-of-care test revolutionizes toxoplasmosis screening

An inexpensive, accurate test that detects infections with the parasite Toxoplasma gondii can provide results within 30 minutes from a finger-prick in a doctor's office or within an hour from a small blood sample tested in a local medical laboratory.

28 May 2024

New antibody therapy shows promise in combating kidney transplant rejection

Antibody-mediated rejection (AMR) is one of the most common causes of kidney transplant failure. To date, however, no treatment has proven effective in combating this complication in the long term.

27 May 2024

Hybrid technique identifies anti-nephrin autoantibodies as biomarker for kidney disorders with nephrotic syndrome

A groundbreaking study, presented today at the 61st ERA Congress, has uncovered a significant breakthrough in the diagnosis and monitoring of kidney diseases associated with nephrotic syndrome.

25 May 2024

Evolving treatment paradigms in multiple myeloma could improve patient outcomes

The treatment landscape for multiple myeloma, the second most common blood cancer, is shifting rapidly, with newly diagnosed patients increasingly being treated with a four-part drug combination that includes a new immunotherapy agent.

24 May 2024

Phase 1 trial for EBC-129 progresses into dose expansion

The Experimental Drug Development Centre (EDDC), Singapore's national platform for drug discovery and development, is pleased to announce that the Phase 1 trial for EBC-129 has progressed into dose expansion.

24 May 2024

Clues from bird flu’s ground zero on dairy farms in the Texas Panhandle

In early February, dairy farmers in the Texas Panhandle began to notice sick cattle. The buzz soon reached Darren Turley, executive director of the Texas Association of Dairymen: "They said there is something moving from herd to herd."

23 May 2024

Dupilumab shows promise in cutting COPD flare-ups and boosting lung function

Dupilumab significantly reduces exacerbations and improves lung function in COPD patients with elevated eosinophil counts, confirming the efficacy of targeting type 2 inflammation.

22 May 2024

Review highlights the rapidly evolving landscape of hepatocellular carcinoma treatment

Hepatocellular carcinoma (HCC), a prevalent form of cancer, profoundly influences the progression and prognosis of the disease through immune response mechanisms.

22 May 2024

Single-cell analysis reveals insights into immune responses during xenotransplantation

Surgical teams at NYU Langone Health performed the world's first genetically modified pig kidney transplants into a human body in September and November 2021, and then transplanted two pig hearts in the summer of 2022.

22 May 2024

Aptamer and Timser partner to deliver world’s first blood test for cervical cancer

Aptamer Group plc (AIM: APTA), the developer of novel Optimer® binders to enable innovation in the life sciences industry, has signed an agreement with Timser Group, a pharmaceutical company focused on women’s health, with a deal value of up to £465,000.

From Aptamer Group 22 May 2024

Tailored antibody-drug conjugate offers hope for aggressive breast cancer

Scientists have used breast cancer cells' weakness against themselves by linking a tumour-selective antibody with a cell-killing drug to destroy hard-to-treat tumors.

21 May 2024

Exercise enhances efficacy of antibody therapy in leukemia patients

Bouts of moderate-to-vigorous intensity exercise could improve the efficacy of antibody therapies used to treat chronic lymphocytic leukemia, new research has shown.

21 May 2024

Dupilumab shows promising results in Phase 3 trial for COPD with type 2 inflammation

Chronic obstructive pulmonary disease patients with type 2 inflammation may soon gain access to a new drug -; dupilumab -; that showed rapid and sustained improvements in patients in a pivotal Phase 3 clinical trial, researchers report in the New England Journal of Medicine.

20 May 2024

Antibody News and Research

Further Reading

Engineered immunogens show promise in inducing HIV broadly neutralizing antibodies

New antibody shows promise as universal weapon against COVID-19 variants

New type of immunotherapy shows promising preclinical results against osteosarcoma

RNA-based therapy shows promise in reducing cholesterol and triglycerides

Vaccination remains crucial for preventing avian influenza spread, says study

Novel method creates antibody-peptide inhibitor conjugates with enhanced therapeutic efficacy

Targeting CD47 to improve osimertinib efficacy in EGFR mutant NSCLC

New point-of-care test revolutionizes toxoplasmosis screening

New antibody therapy shows promise in combating kidney transplant rejection

Hybrid technique identifies anti-nephrin autoantibodies as biomarker for kidney disorders with nephrotic syndrome

Evolving treatment paradigms in multiple myeloma could improve patient outcomes

Phase 1 trial for EBC-129 progresses into dose expansion

Clues from bird flu’s ground zero on dairy farms in the Texas Panhandle

Dupilumab shows promise in cutting COPD flare-ups and boosting lung function

Review highlights the rapidly evolving landscape of hepatocellular carcinoma treatment

Single-cell analysis reveals insights into immune responses during xenotransplantation

Aptamer and Timser partner to deliver world’s first blood test for cervical cancer

Tailored antibody-drug conjugate offers hope for aggressive breast cancer

Exercise enhances efficacy of antibody therapy in leukemia patients

Dupilumab shows promising results in Phase 3 trial for COPD with type 2 inflammation

Antibodies eBook

Discover how SciY empowers scientists

Why use light scattering to analyze proteins and viral vectors?

Changing the landscape of R&D to build clinical success from the ground up

Latest Life Science News